HC Wainwright Reiterates “Buy” Rating for Kodiak Sciences (NASDAQ:KOD)

Kodiak Sciences (NASDAQ:KOD)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $58.00 price target on the stock, up from their prior price target of $38.00. HC Wainwright’s price target suggests a potential upside of 45.88% from the company’s current price.

Several other research analysts also recently commented on KOD. UBS Group started coverage on shares of Kodiak Sciences in a report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 target price on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Kodiak Sciences in a report on Thursday, January 22nd. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.14.

Kodiak Sciences Trading Up 74.8%

Shares of Kodiak Sciences stock opened at $39.76 on Friday. The firm has a fifty day simple moving average of $24.95 and a 200-day simple moving average of $21.62. Kodiak Sciences has a 1-year low of $1.92 and a 1-year high of $40.46. The stock has a market capitalization of $2.11 billion, a price-to-earnings ratio of -9.65 and a beta of 2.61.

Institutional Investors Weigh In On Kodiak Sciences

Several hedge funds have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC increased its stake in Kodiak Sciences by 1,221.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock valued at $28,000 after acquiring an additional 916 shares during the period. GF Fund Management CO. LTD. acquired a new position in Kodiak Sciences in the 4th quarter valued at approximately $29,000. Headlands Technologies LLC raised its holdings in Kodiak Sciences by 256.4% in the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock valued at $30,000 after acquiring an additional 5,815 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Kodiak Sciences in the 4th quarter worth approximately $72,000. Finally, Strs Ohio bought a new stake in shares of Kodiak Sciences in the 4th quarter worth approximately $87,000. Institutional investors own 89.06% of the company’s stock.

Key Headlines Impacting Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: GLOW2 Phase 3 topline showed Zenkuda superiority vs. sham, with 62.5% of treated patients achieving a ≥2‑step DRSS improvement vs. 3.3% for sham—supporting efficacy across two Phase 3 studies and setting up a likely BLA submission. Kodiak Sciences Announces Positive Topline Results in GLOW2
• Positive Sentiment: Major news outlets and financial press reported the successful late‑stage readout, triggering broad market buying and coverage that is amplifying investor interest. Reuters: Kodiak Sciences shares surge after eye drug succeeds in late-stage study
• Positive Sentiment: Industry press expects a Biologics License Application (BLA) filing next after the two positive Phase 3 studies, which would move Zenkuda toward regulatory review and potential commercialization. Bioworld: Kodiak’s Zenkuda sparkles in Glow2, BLA filing next
• Neutral Sentiment: Financial outlets and market movers lists highlighted KOD among the biggest gainers after the readout; this increases visibility but also invites short‑term trading and coverage-driven volatility. Seeking Alpha: Kodiak posts trial win
• Neutral Sentiment: Unusual options activity was reported—3,472 put options traded (a ~1,256% increase versus typical daily put volume)—which could reflect hedging by longs or speculative bets and may add intraday implied‑volatility pressure. (No direct article linked)
• Negative Sentiment: After a large one‑day rally the stock is potentially vulnerable to profit‑taking and heightened volatility; KOD has a high beta and a wide gap between current price and longer‑term moving averages, so technical pullbacks are possible.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.